GlobeNewswire by notified

SalMar - Merger between SalMar and NRS completed – new share capital

Share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN CANADA, AUSTRALIA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Frøya, 7 November 2022

Reference is made to the stock exchange announcement made by SalMar ASA (“SalMar”) on 31 October 2022 in connection with the recommended voluntary offer by SalMar (the "Offeror") to acquire all outstanding shares in NTS ASA (“NTS”) (the "Offer") and the merger between SalMar and Norway Royal Salmon ASA (“NRS”) (the “Merger”).

The Merger has after close of trading on Oslo Børs today (the “Merger Effective Date”) been completed by registration in the Norwegian Register of Business Enterprises. Consequently, the last day of trading in the NRS shares was today. The Merger contemplates that SalMar will absorb all assets, rights and obligations of NRS and that NRS is dissolved. Shareholders of NRS will receive merger consideration consisting of 0.303933 shares in SalMar and NOK 52.84 in cash for each share in NRS they own as at the expiry of the Merger Effective Date, as such shareholders appear in NRS’ shareholders register with Euronext Securites Oslo (VPS) as at the expiry of 9 November 2022 (the record date for the Merger).

The merger consideration shares are expected to be delivered to eligible recipients’ securities accounts with the VPS on 11 November 2022. Any trades by investors prior to delivery of the merger consideration shares must be carried out in compliance with applicable short sale and other regulations.

As a result of the Merger, SalMar has issued 17,851,550 new shares as merger consideration, and its new share capital is NOK 33,912,887.25 divided into 135,651,549 shares each share with a par value NOK 0.25.

Reference is made to the stock exchange announcement from SalMar on 31 October 2022 for information on settlement of the Offer.

Arctic Securities AS acts as financial advisor and receiving agent and Advokatfirmaet BAHR AS acts as legal advisor to SalMar.

For further information, please contact:

Håkon Husby, head of IR SalMar
Tel: +47 936 30 449
Email: hakon.husby@salmar.no

This information is information required to be made public pursuant to the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. The information was submitted by Håkon Husby at 20:00 (Norwegian time) on 7 November 2022.

About SalMar

SalMar is one of the world's largest and most efficient producers of salmon. The group has farming operations in Central Norway, Northern Norway and Iceland, as well as substantial harvesting and secondary processing operations in Norway, at InnovaMar in Frøya, InnovaNor in Senja and Vikenco in Aukra. In addition, the company is operating within offshore aquaculture through the company SalMar Aker Ocean. SalMar also owns 50% of the shares in Scottish Sea Farms Ltd.

See www.salmar.no for more information about SalMar.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release

The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release

EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp

Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release

Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un

ForFarmers trading update Q1 2024: Like-for-like volume growth and strong increase operational profitability2.5.2024 07:00:00 CEST | Press release

Lochem, 2 May 2024 ForFarmers trading update Q1 2024 Like-for-like volume growth and strong increase operational profitability Pieter Wolleswinkel, CEO ForFarmers: “Our (compound) feed volumes show an increase. This is a great achievement and shows that we have been able to further strengthen our market position with our focused local market approach. The volume development confirms that we are contributing to a good return on the farm/a profitable farming business. Our effective buying and selling strategy where we operate close to the market, combined with our actions to reduce our cost base, significantly improved operating profitability in the first quarter. The integration of Piast's operations in Poland is progressing well. The reorganisation in the United Kingdom is also on schedule. These developments show that we are on the right track with our strategic initiatives. This strengthens our confidence in achieving our set return target. At the same time, we continue to invest in

HiddenA line styled icon from Orion Icon Library.Eye